Hannouf M, et al. Cost-effectiveness analysis of multigene expression profiling assays to guide adjuvant therapy decisions in women with invasive early-stage breast cancer. Pharmacogenomics J. 2020 Feb; 20(1):27-46.
Beauchamp, K.A., Johansen Taber, K.A. & Muzzey, D. Clinical impact and cost-effectiveness of a 176-condition expanded carrier screen. Genet Med 21, 1948–1957 (2019). https://doi.org/10.1038/s41436-019-0455-8
Del Tredici A, et al. Real-wold iimpact of pharmacogenomic testing on medication use and healtchare resource utilization in patients with major depressive disorder. J Clin Psychopharmacol. 2025 Jul-Aug(4):320-328
Tanner JA, et al. Canadian medication cost savings associated with combinatorial pharmacogenomic guidance for psychiatric medications. ClinicoEconomics and Outcomes Research. 9 December 2019; 2019(11):779-87.
Benitez J, et al. Use of combinatorial pharmacogenomic guidance in treating psychiatric disorders: financial impact on a health plan. Per Med 2018 Nov; 15(6):481-94.
Winner JG, et al. Psychiatric pharmacogenomics predicts health resource utilization of outpatients with anxiety and depression. Transl Psychiatry 2013 Mar 19; 3:e242.
Winner JG, et al. Combinatorial pharmacogenomic guidance for psychiatric medications reduces overall pharmacy costs in a 1 year prospective evaluation. Curr Med Res Opin 2015 Sep; 31(9):1633-43.
Hornberger J, et al. Cost-effectiveness of combinatorial pharmacogenomic testing for treatment resistant MDD patients. The American Journal of Managed Care 2015 August; 21(6):e357-65.
Byfield, SD. et al. Economic impact of multigene panel testing for hereditary breast and ovarian cancer. J Comp Eff Res. 2021 Feb;10(3):207-217.
Smith S, et al. Optimization of quality assurance to increase clinical utility and cost effectiveness of hereditary cancer testing. Per Med 2017; 14(3), 213-20.
Gustavsen G, et al. Health economic impact of a biopsy-based cell cycle gene expression assay in localized prostate cancer. Future Oncol. 2020 Dec;16(36):3061-3074.